Ozempic, the once-weekly injector pen that made Novo Nordisk one of the most valuable companies in Europe, carries a US list price of roughly $969 for a month’s supply — and the same pen, filled with the same semaglutide, sells in Germany for around €59 through the statutory insurance system. The molecule is identical. The factory in Kalundborg, on the Danish coast, is often the same. The gap between the two prices is one of the largest for any prescription drug on Earth, and the reason it exists winds back to a rescue mission carried out by a Danish Nobel laureate in 1922.
The White House put the disparity in writing in May 2026, when it laid out its Most-Favored-Nation drug pricing framework. Americans, the brief noted, routinely pay three to ten times what patients in peer countries pay for the exact same branded medication. Ozempic and its sister drug Wegovy sit near the top of that list.
The story of how a Danish injectable ended up costing an American nurse more than her car payment starts with a dying fourteen-year-old boy in Toronto.
The rescue in Toronto, 1922
Leonard Thompson was slipping into a diabetic coma at Toronto General Hospital when Frederick Banting and Charles Best injected him with a pancreatic extract in January 1922. The first dose was impure and caused an abscess. A second, refined by biochemist James Collip, worked. Thompson survived for years after the treatment.
Banting and John Macleod won the Nobel Prize in 1923. Banting split his share with Best. Macleod split his with Collip. And the team sold the patent to the University of Toronto for a nominal fee, because, as Banting put it, insulin belonged to the world.
Watching from Copenhagen was August Krogh, a Danish physiologist and Nobel laureate. His wife Marie was a diabetic. In 1922 the Kroghs traveled to North America. They came home with a license to manufacture insulin in Scandinavia. That license became Nordisk Insulinlaboratorium, which eventually merged with a rival called Novo to form Novo Nordisk.
A foundation, not a family
Nordisk was structured from the beginning as a non-profit — its shares were held by a foundation whose charter required that surplus be reinvested in diabetes research or given away. When Nordisk and Novo merged, the resulting company kept that structure. Today the Novo Nordisk Foundation owns the controlling voting stake in the pharmaceutical company and is, by asset value, one of the largest philanthropic foundations in the world.
Which means the company that sells Ozempic is legally bound to plough profits back into medical research and public health. It is a Danish corporate form with no real American analog, and it shapes how Novo Nordisk prices its drugs in the country of its birth. In Denmark and across most of Europe, semaglutide is treated as what it descends from: a diabetes therapy, a public good, a molecule handed off for a dollar a hundred years ago.
What semaglutide actually does
Semaglutide is a GLP-1 receptor agonist — a synthetic version of a gut hormone the body releases after eating. It tells the pancreas to release insulin, tells the liver to hold back glucose, and tells the brain, quite loudly, that the stomach is full. GLP-1 drugs like Ozempic, Wegovy, Mounjaro and Zepbound work by mimicking that hormone and staying in the bloodstream for days rather than minutes.
The weight loss was, for years, considered a side effect. Then the trial data came in. Patients on the highest doses experienced significant weight loss. In cardiovascular outcome trials, they had fewer heart attacks and strokes. In kidney trials, fewer instances of renal decline. The drug that started as a diabetes therapy turned into something closer to a metabolic reset button.
By 2026, according to Forbes Health’s compilation of GLP-1 statistics, roughly 1 in 8 American adults had tried a GLP-1 medication at some point, and prescriptions had climbed into the tens of millions per year.
The $969 pen and the €59 pen
Here is where geography starts to bite. In the United States, Ozempic’s list price is $968.52 for a month’s supply of the 1-mg dose. Wegovy, the higher-dose version approved specifically for weight loss, lists at a higher price point. American patients with commercial insurance often pay a fraction of that through rebates and copays. Patients without insurance, or with plans that exclude weight-loss drugs, pay something close to the sticker.
In Germany, the same 1-mg Ozempic pen is reimbursed by statutory health insurance at roughly €59 for the same monthly supply. In France and the United Kingdom, prices are similarly lower than in the United States. In Denmark, where the drug is manufactured, the price is lower still.
The active ingredient is bioequivalent across all of them. The manufacturing standards are identical — Novo Nordisk’s Kalundborg plant supplies most of the world.
Why the numbers diverge
Three mechanisms do most of the work.
The first is reference pricing. Germany’s statutory insurers, France’s Assurance Maladie, the UK’s NICE — they all negotiate collectively on behalf of tens of millions of patients and refuse to reimburse above a benchmark tied to therapeutic value. If Novo Nordisk wants access to those markets, it accepts the reference price or walks away. It rarely walks away.
The second is the American Pharmacy Benefit Manager system. Between Novo Nordisk and the patient sits a PBM — CVS Caremark, Express Scripts, OptumRx — that negotiates rebates in exchange for placing the drug on a formulary. Those rebates can substantially reduce the list price, but they are opaque, they are pocketed partly by the PBM itself, and the list price stays high because the rebate is calculated as a percentage of it. The uninsured patient at the counter sees the list, not the rebate.
The third is what the White House brief calls the innovation subsidy. American consumers, the analysis argued, effectively fund the global pharmaceutical R&D bill because they pay unregulated prices while every other wealthy country negotiates them down. The MFN framework proposes to tie US prices to the lowest paid by any peer nation — a policy that, if enforced, would significantly cut Ozempic’s American price.
The competition arriving
Novo Nordisk no longer has the market to itself. Eli Lilly’s tirzepatide — sold as Mounjaro for diabetes and Zepbound for weight loss — hits both the GLP-1 and GIP receptors, and in head-to-head trials produced greater weight loss than semaglutide. Lilly’s market capitalisation blew past Novo Nordisk’s in 2024, and by mid-2026 Lilly was racing toward a trillion-dollar valuation while Novo’s stock had shed a large chunk of its 2023 peak.
The Danish company has responded by cutting prices in specific channels. Its direct-to-consumer NovoCare Pharmacy started offering Wegovy at $499 a month to cash-paying US patients in 2025, and further pricing shifts followed in 2026 as the company tried to defend market share against Lilly.
Even at $499, that is more than eight times what a German patient pays through statutory insurance for the equivalent dose.
The Danish echo
The Novo Nordisk Foundation, meanwhile, keeps doing what August Krogh’s charter told it to do. It has committed substantial funding to metabolic research at the University of Copenhagen. It funds antibiotic resistance work, quantum computing, and a global diabetes prevention program. The foundation has, over its history, given away tens of billions of Danish kroner.
The Ozempic revenue that funds those grants comes disproportionately from the United States. American prescriptions have accounted for a substantial portion of Novo Nordisk’s GLP-1 sales, even as European volumes grew. Analysts tracking the company have pointed out that a US price cut on the scale the MFN framework proposes would reshape the foundation’s giving capacity, and by extension, a slice of European biomedical philanthropy.
Which is the strange loop the century-old rescue mission has produced. A Canadian discovery, handed off for a dollar in 1922, was carried to Denmark by a physiologist trying to save his wife. It became a non-profit-owned company that now sells the world’s most sought-after weight-loss drug. The Americans paying $969 a month are, in a roundabout way, funding Danish research grants that trace back to Frederick Banting’s refusal to profit from insulin.
What Leonard Thompson would recognise
Thompson, the boy who lived, spent the rest of his life injecting insulin. The pen he would use today looks almost nothing like the glass syringe of pork-pancreas extract that Banting handed to the ward nurse in 1922. It is a plastic auto-injector the size of a highlighter, and the molecule inside is a designed one — a re-engineered version of a natural human gut hormone, born of a drug class first inspired by the venom of the Gila monster, tuned to last a week in the bloodstream.
The price he would pay for that pen depends, more than on anything about the science, on which passport he holds. A German pension gets him the drug for the price of a nice dinner. An American paycheck, without the right insurance, gets him a bill roughly sixteen times larger. The molecule is the same. The pharmacy shelf is the same. The century between Toronto and Kalundborg is the same.
Only the invoice, in the end, tells you where you are standing.
